Cerus Stock Forecast, Price & News

Cerus (NASDAQ:CERS) Frequently Asked Questions

How has Cerus' stock been impacted by COVID-19?

Cerus' stock was trading at $4.76 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CERS shares have increased by 37.0% and is now trading at $6.52.
View which stocks have been most impacted by COVID-19.

When is Cerus' next earnings date?

Cerus is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Cerus.

How were Cerus' earnings last quarter?

Cerus Co. (NASDAQ:CERS) announced its quarterly earnings data on Tuesday, November, 2nd. The biotechnology company reported ($0.07) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.10) by $0.03. The biotechnology company earned $36.13 million during the quarter, compared to analyst estimates of $31.60 million. Cerus had a negative trailing twelve-month return on equity of 65.94% and a negative net margin of 50.03%. During the same quarter in the previous year, the business earned ($0.08) earnings per share.
View Cerus' earnings history.

What guidance has Cerus issued on next quarter's earnings?

Cerus issued an update on its FY 2021 earnings guidance on Tuesday, November, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $127 million-$129 million, compared to the consensus revenue estimate of $144.25 million.

Who are Cerus' key executives?

Cerus' management team includes the following people:

• Obi Greenman, President, Chief Executive Officer & Director
• Vivek K. Jayaraman, Chief Operating Officer (LinkedIn Profile)
• Kevin Dennis Green, Chief Financial Officer & Vice President-Finance (LinkedIn Profile)
• Laurence M. Corash, Chief Scientific Officer (LinkedIn Profile)
• Carol M. Moore, Senior VP-Regulatory Affairs, Quality & Clinical (LinkedIn Profile)

What is William M. (Obi) Greenman's approval rating as Cerus' CEO?

15 employees have rated Cerus CEO William M. (Obi) Greenman on Glassdoor.com. William M. (Obi) Greenman has an approval rating of 35% among Cerus' employees. This puts William M. (Obi) Greenman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Cerus' key competitors?

Some companies that are related to Cerus include Align Technology (ALGN), West Pharmaceutical Services (WST), Cooper Companies (COO), DENTSPLY SIRONA (XRAY), Quidel (QDEL), ICU Medical (ICUI), STAAR Surgical (STAA), Neogen (NEOG), Merit Medical Systems (MMSI), Haemonetics (HAE), Atrion (ATRI), Meridian Bioscience (VIVO), OraSure Technologies (OSUR), Anika Therapeutics (ANIK) and Antares Pharma (ATRS).
View all of CERS's competitors.

What other stocks do shareholders of Cerus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerus investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Pfizer (PFE), Immunomedics (IMMU), Exelixis (EXEL), Novavax (NVAX) and NVIDIA (NVDA).

What is Cerus' stock symbol?

Cerus trades on the NASDAQ under the ticker symbol "CERS."

Who are Cerus' major shareholders?

Cerus' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.80%), Sumitomo Mitsui Trust Holdings Inc. (7.16%), Nikko Asset Management Americas Inc. (7.13%), Primecap Management Co. CA (5.81%), Wasatch Advisors Inc. (4.76%) and Geode Capital Management LLC (1.87%). Company insiders that own Cerus stock include Carol Moore, Chrystal Menard, Daniel N Swisher Jr, Gail Schulze, Kevin Dennis Green, Laurence M Corash, Richard J Benjamin, Timothy B Anderson, Timothy L Moore, Vivek K Jayaraman, Vivek K Jayaraman and William Mariner Greenman.
View institutional ownership trends for Cerus.

Which institutional investors are selling Cerus stock?

CERS stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Morgan Stanley, Renaissance Technologies LLC, Peregrine Capital Management LLC, First Midwest Bank Trust Division, Two Sigma Investments LP, and Alliancebernstein L.P.. Company insiders that have sold Cerus company stock in the last year include Carol Moore, Chrystal Menard, Daniel N Swisher Jr, Gail Schulze, Kevin Dennis Green, Laurence M Corash, Timothy B Anderson, Vivek K Jayaraman, and William Mariner Greenman.
View insider buying and selling activity for Cerus or view top insider-selling stocks.

Which institutional investors are buying Cerus stock?

CERS stock was bought by a variety of institutional investors in the last quarter, including Polar Capital Holdings Plc, Granahan Investment Management Inc. MA, Wasatch Advisors Inc., UBS Group AG, Bamco Inc. NY, Altium Capital Management LP, King Luther Capital Management Corp, and Bouvel Investment Partners LLC.
View insider buying and selling activity for Cerus or or view top insider-buying stocks.

How do I buy shares of Cerus?

Shares of CERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cerus' stock price today?

One share of CERS stock can currently be purchased for approximately $6.52.

How much money does Cerus make?

Cerus has a market capitalization of $1.12 billion and generates $91.92 million in revenue each year. The biotechnology company earns $-59.86 million in net income (profit) each year or ($0.35) on an earnings per share basis.

How many employees does Cerus have?

Cerus employs 266 workers across the globe.

When was Cerus founded?

Cerus was founded in 1991.

What is Cerus' official website?

The official website for Cerus is www.cerus.com.

Where are Cerus' headquarters?

Cerus is headquartered at 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520.

How can I contact Cerus?

Cerus' mailing address is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. The biotechnology company can be reached via phone at (925) 288-6000, via email at [email protected], or via fax at 925-288-6001.